Research & Development

A globally recognized hub for life sciences and health innovation, and the third-largest biopharma cluster in the country, Montgomery County, Maryland, drives breakthroughs across cell and gene therapy, advanced biologics, and biopharmaceuticals. Its diverse ecosystem includes leading clinical biotech firms, contract research organizations, advanced biomanufacturing, and process technology companies, as well as companies specializing in medical devices, MedTech innovation, digital health, and AI-enabled diagnostics. Together, these capabilities help accelerate the development and delivery of next-generation solutions that advance healthcare and improve health outcomes worldwide.

18

federal agency
headquarters

40K

life sciences
workers

$3.62B

of VC invested in biotech and drug discovery (2021-2025)

Cell & Gene Therapy, Advanced Biologics

Montgomery County’s life sciences sector offers cell and gene therapy companies unparalleled proximity to the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI), and the broader federal biomedical research community. This unique concentration of institutions provides direct access to world-class scientific talent, regulatory expertise, and translational research infrastructure, creating a significant competitive advantage for companies developing and commercializing next-generation therapies.

Biopharmaceuticals & Clinical Biotech

Companies across the County are developing therapeutics targeting oncology, rare diseases, neuroscience, infectious diseases, and immune-mediated conditions, reflecting the depth and diversity of the local biotechnology ecosystem. The presence of both commercial-stage and clinical-stage innovators is a testament to the County’s strength in advancing therapies from development through commercialization.

Contract Research Organizations (CROs)

Montgomery County’s contract research and research services sector benefits from strong connections to federal biomedical agencies, leading research institutions, nonprofit organizations, and biopharmaceutical companies. This concentration of expertise supports specialized capabilities in clinical research, biomedical informatics, regulatory science, program management, and evidence generation, helping accelerate innovation and bring new therapies and technologies to market.

Biomanufacturing & Process Technology

Montgomery County’s biomanufacturing and process technology companies encompass expertise across vaccine production, biologics tools, assay platforms, cell-based technologies, and life sciences manufacturing systems. Together, these capabilities strengthen the life sciences sector and support advanced biologics through every stage of development, scale-up, and commercialization.

Medical Devices & MedTech

Companies developing diagnostics, monitoring technologies, laboratory platforms, and specialized clinical tools are advancing innovations that improve disease detection, patient monitoring, and clinical decision-making across a range of healthcare and life sciences applications. Attracted by a highly educated workforce and strong quality of life, these companies are well positioned to attract and retain top talent, as well as secure new investment to support continued growth and innovation.

Digital Health & AI-Enabled Diagnostics

A growing digital health and AI-enabled diagnostics sector brings together companies working across genomics, diagnostics, patient engagement, healthcare analytics, and AI-driven biomedical discovery. Here, they benefit from access to world-class research institutions, a highly skilled talent pool, and a collaborative life sciences environment that supports innovation and commercialization.

MAJOR EMPLOYERS

Proof at every scale.

GLOBAL ENTERPRISES

1,000+ employees

MEDIUM ENTERPRISES

100-999 employees

SMALL ENTERPRISES

< 100 employees

When we decide where to invest, we decide based on a number of factors—talent pool is critical—but also whether the location is business-friendly. That’s the kind of relationship we have with the state of Maryland.

Benjamin Moutier · Senior VP, Vaccines & Immune Therapies, AstraZeneca